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Introduction
Tuberculosis (TB) is a serious threat to human health,[1–3] caus-
ing 1.5 million deaths in 2013.[4,5] The emergence and transmis-
sion of multidrug-resistant (MDR) and extensively drug-resist-
ant (XDR) TB strains is a particular challenge for global TB pre-
vention and treatment.[3] Bedaquiline (1) is the first novel US
Food and Drug Administration (FDA)-approved anti-TB drug
for the treatment of MDR-TB cases in the past 40 years.[6–11] In
vitro studies demonstrated potent inhibition of mycobacterial
growth by bedaquiline, against both drug-sensitive and drug-
resistant mycobacteria, with a minimum inhibitory concentra-
tion (MIC) of 0.06 mgmL@1.[9] Bedaquiline also exhibits excellent
clinical efficacy for the treatment of TB patients, particularly
those with MDR-TB infections.[9] It has a remarkably long half-
life, which was attributed to a high logP value (7.52) and cat-
ionic, amphiphilic properties resulting in tissue accumula-
tion.[8, 12] Adverse side effects of bedaquiline, such as phospholi-
pidosis and cardiovascular risks, may relate to these molecular
features. In particular, an N-desmethyl metabolite (“M2”) was
reported to be more toxic but less bactericidal.[8, 13] At the mo-
lecular level the compound was shown to inhibit the mycobac-
terial F1Fo ATP synthase by binding to its membrane-embed-
ded Fo rotor ring, a ring-shaped assembly of identical c-subunit
copies.[6, 14] Here, the half-maximal inhibitory concentration
(IC50) of bedaquiline, efficiently inhibiting the mycobacterial
ATP synthase, was reported to be remarkably low (25 nm). Fur-
thermore, the mode of action of bedaquiline is highly target
specific,[14] as the IC50 values for human, bovine, and mouse mi-
tochondrial ATP synthases were found to be 20000-fold
higher.[10,14, 15]
Besides these obvious assets of bedaquiline, its chemical
complexity in harboring two adjacent chiral centers, makes the
chemical synthesis of this new anti-TB drug laborious and
costly in the production process.[11,16] Many ongoing research
programs are focused on the optimization of bedaquiline to
decrease its structural complexity while maintaining its antitu-
bercular activity.[17–24] Still, new bedaquiline analogues are re-
quired to deliver potential new leads.
Bedaquiline (BDQ) is a novel and highly potent last-line antitu-
berculosis drug that was approved by the US FDA in 2013.
Owing to its stereo-structural complexity, chemical synthesis
and compound optimization are rather difficult and expensive.
This study describes the structural simplification of bedaquiline
while preserving antitubercular activity. The compound’s struc-
ture was split into fragments and reassembled in various com-
binations while replacing the two chiral carbon atoms with an
achiral linkage instead. Four series of analogues were de-
signed; these candidates retained their potent antitubercular
activity at sub-microgram per mL concentrations against both
sensitive and multidrug-resistant (MDR) Mycobacterium tuber-
culosis strains. Six out of the top nine MIC-ranked candidates
were found to inhibit mycobacterial ATP synthesis activity with
IC50 values between 20 and 40 mm, one had IC50>66 mm, and
two showed no inhibition, despite their antitubercular activity.
These results provide a basis for the development of chemical-
ly less complex, lower-cost bedaquiline derivatives and de-
scribe the identification of two derivatives with antitubercular
activity against non-ATP synthase related targets.
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The aim of this study was therefore to simplify the chemical
synthesis of bedaquiline to work toward new, alternative leads.
Once these simplified scaffolds are achieved, they will be used
to improve pharmacokinetic properties to decrease the ad-
verse side effects of bedaquiline. Based on the previously re-
ported relationship of structure and antitubercular activity of
various diarylquinoline analogues,[9] we dissected bedaquiline
into various fragments and reorganized them to obtain novel
antitubercular agents with simplified scaffolds. The MIC values
of the new compounds were determined, and the best nine
candidates were tested for their inhibitory activities against
ATP synthesis inhibition in mycobacteria.
Results and Discussion
Design strategy
Bedaquiline (1) contains two adjacent chiral carbon atoms that
bridge three aryl rings and a dimethylaminoethyl moiety
(Figure 1). The structure and antitubercular activity relationship
of diarylquinoline analogues as well as the importance and
contribution of each fragment of bedaquiline to its antituber-
cular activity have been quantitatively evaluated.[9] It was
shown that the activity of bedaquiline is closely related to the
spatial distribution of its segments. Some fragments, such as
the quinolino and dimethylamino groups, are necessary to
maintain its activity, whereas other groups such as the bromo
and hydroxy groups are less important. Therefore, we split be-
daquiline into the core quinoline moiety, three major frag-
ments (phenyl ring, naphthylmethyl, and dimethylaminoethyl),
and two minor fragments (bromo and hydroxy) (Figure 1). We
then reassembled the quinoline core with three major frag-
ments to design four new series of scaffolds. Notably, previous
structure–activity relationship (SAR) studies of bedaquiline and
its analogue 2 suggested that the naphthylmethyl group can
be replaced with a substituted benzyl ring.[9] Thus, in our
chemical optimization, we also used the substituted benzyl
ring instead of a naphthylmethyl group to design some new
compounds. In addition, the minor bromo and hydroxy groups
were added to the final compounds, as desired.
In series 1, fragments A and C were attached to the tertiary
carbon atom at the 3-position of the quinoline moiety, and
fragment B was attached to fragment A. In series 2, fragment-
s A and C were attached to the tertiary carbon at the 3-posi-
tion, while fragment B was attached to fragment C. In series 3,
fragments A and B were attached to the tertiary carbon at the
3-position, while fragment C was moved down to the 2-oxyl
position. Finally, in series 4 fragment A was attached to the 3-
position of the quinoline moiety, fragment B was attached to
fragment A, and fragment C was moved down to the 2-oxyl
position. From series 1 to 4, we systematically simplified the
structure of bedaquiline to remove the two chiral carbons and
to understand the structure antimycobacterial activity relation-
ship of these new analogues.
First round of optimization
Compounds of series 1
The synthesis of compound 6 (Scheme 1) began with a nucleo-
philic addition of (3-fluorobenzyl)magnesium bromide to 2-me-
thoxyquinoline-3-carbaldehyde to give 4. Intermediate 4 was
Figure 1. Strategy of bedaquiline simplification. Bedaquiline was split into the core quinoline moiety, three major and two minor fragments (bromo and hy-
droxy groups). The major fragments comprise the phenyl ring (fragment A), the side chain dimethylaminoethyl (fragment B), and the naphthylmethyl ring
(fragment C). These major fragments were reattached to the core quinoline moiety to design four series of new analogues while gradually replacing the
chiral linkage.
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oxidized with Dess–Martin periodinane to produce 5,[25] which
was reacted with an appropriate Grignard reagent to give 6.
Compound 10 (Scheme 2) was obtained by reacting 2-methox-
yquinoline-3-carbaldehyde with (2-((dimethylamino)methyl)-
phenyl)magnesium bromide to produce intermediate 8. Oxidiz-
ing 8 with TBAP/NMO in 1,4-dioxane afforded 9,[26] which was
then treated with a Grignard reagent to give 10.
In series 1 (Table 1), we designed compounds, in which frag-
ment B was attached to fragment A. In total, eight compounds
were synthesized, which provided primary information about
the SAR of the compounds in series 1. An antitubercular activi-
ty screening revealed that compound 6a has the most potent
antitubercular activity (1 mgmL@1) in this series of compounds,
while the growth of mammalian cells was inhibited with
CC50>64 mgmL
@1. An identical molecule, 10a, harboring a bro-
mide, is less active, suggesting that it is not required to pre-
serve antitubercular activity. In addition, relative to compound
10a, compound 10b has an additional methylene unit exten-
sion between fragment C and the other segments. However,
compound 10b shows less potency against the growth of my-
cobacterium. Thus, the greater distance between fragment C
and the main scaffold likely disfavors its antitubercular activity.
Other analogues from this series with similar structures exhibit-
ed only weak activity against mycobacteria, indicating that the
arrangement of the fragments in series 1 is not suitable to ach-
ieve the desired antimycobacterial activity. Note that all candi-
dates of this series still contain one chiral carbon, and racemic
mixtures were used to generate CC50 and MIC values.
Compounds of series 2
Aniline (11) reacted with hydrocinnamoyl chloride to afford 12,
which was then treated with phosphoryl chloride and DMF at
100 8C to provide 13 (Scheme 3). The reaction of 13 with
sodium methoxide produced 14 via a SN2 reaction. Next, 14
was activated by N-bromosuccinimide (NBS) to make 15. The
intermediate 15 was treated with substituted aniline and po-
tassium carbonate at room temperature, or followed by a reac-
tion with various aminoalkyl bromides to produce 16. The syn-
thesis of the derivatives required minor modifications (Sup-
porting Information).
In series 2 (Table 2), fragment B was attached to fragment C.
The nitrogen or oxygen atoms located close to fragment C
were placed to mimic the hydroxy group of bedaquiline. A
Scheme 1. Synthesis of compound 6. Reagents and conditions : a) (3-fluoro-
benzyl)magnesium bromide, THF, RT, 2 h, 66.5%; b) Dess–Martin periodinane,
CH2Cl2, RT, 3 h, 94.8%; c) substituted phenylmagnesium bromide, THF, RT,
2 h, 56.1–86.9%.
Scheme 2. Synthesis of compound 10. Reagents and conditions : a) (2-((dime-
thylamino)methyl)phenyl)magnesium bromide, THF, RT, 2 h, 72.1–83.8%;
b) TBAP/NMO, 1,4-dioxane, RT, 15 h, 77.2–87.5%; c) Grignard reagent, THF,
RT, 2 h, 38.1–56.2%.
Scheme 3. Synthesis of N-linked compounds 16. Reagents and conditions : a) hydrocinnamoyl chloride, Et3N, CH2Cl2, RT, 5 h, 93.6–98.2%; b) POCl3, DMF, 100 8C,
16 h, 46.0–82.2%; c) NaOMe/MeOH, reflux, 6 h, 98.2–99.3%; d) NBS/CCl4, reflux, 3 h; e) 1. substituted aniline, K2CO3, DMF, RT, 2 h, or 2. multistep (see Support-
ing Information for details).
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total of six compounds were synthesized in this series. The ac-
tivity screening revealed that most of the compounds in
series 2 exhibit moderate antitubercular activity. Compound
16e, however, was nearly inactive, which might have been
caused by the very short distance between the terminal amine
and fragment C of the molecule. In addition, we can also con-
clude from series 2 that the bromide is not important to retain
the antitubercular activity of this compound type. Further-
more, there is one chiral carbon left in the structures of all can-
didates in this series, and the racemic mixtures were used to
generate CC50 and MIC values. As none of the compounds
from series 2 exhibited sufficient antimycobacterial activity in
the very low-micromolar range, these compounds were not
chosen for further chemical optimization.
Compounds of series 3
The preparation of compounds 22–24 (Scheme 4) started from
2-chloroquinoline-3-carbaldehyde (17) with methylmagnesium
iodide or phenylmagnesium bromide to provide secondary al-
cohol intermediates 18. The oxidation of two 18 analogues
with Dess–Martin periodinane produced 19, which was then
reacted with 1-naphthol to give 20. The synthesis of 22 was
completed by the condensation of 20 with hydroxylamine hy-
drochloride, and dimethylaminoethyl chloride successively. The
treatment of 20 with (3-(dimethylamino)propyl)magnesium
chloride gave 23. Compound 24 was obtained by heating 23
under acidic conditions (25% w/w hydrochloric acid in alco-
hol).
In series 3 (Table 3) fragments A and B were joined with
a methylene linker forming a planar configuration. In addition
fragment C was added to the quinoline core by an ether bond.
This structure allowed us to remove the two chiral carbons. Ac-
cording to this strategy, we synthesized compounds 22 and
24. Compound 23 was synthesized for structure–activity com-
parison. An antitubercular evaluation showed that all three
compounds (22–24) from this series exert a reasonably potent
activity against mycobacteria. This suggests that placing frag-
Table 1. In vitro antitubercular activity of series 1 compounds.[a]
Compd R1 R2 R3 MIC CC50
[b]
mgmL@1 mm mgmL@1 mm
6a H 1.0 2.3 >64 >148.8
6b H 6.8 15.8 7.6 17.6
6c H >32 >85.8 26 69.7
6d H >32 >67.8 >64 >135.6
10a Br 16 31.5 >64 >126.0
10b Br >32 >63.4 59 117.0
10c Br >32 >61.4 1.4 2.7
10d OCH3 >32 >67.8 >64 >135.6
[a] Reference compound: bedaquiline MIC=0.060 mgmL@1 (0.1 mm). [b] Concentration at which the growth of Vero cells is inhibited by 50%.
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ment C in the 2-methoxyl position maintains the anti-
tubercular activity. The comparison of compounds 23
and 24 further reveals that the planar configuration
between fragments A and B does not affect the anti-
tubercular activity. It also indicates that the hydroxy
group is not important for the antitubercular activity
of this new scaffold. Moreover, none of the com-
pounds from series 3 contains the bromide. Hence it
does not affect the antitubercular activity of this
series of compounds, in agreement with the SAR in-
formation from series 1 and 2.
Compounds of series 4
The design of series 4 compounds was based on the
finding that the planar configuration of compound
24 (series 3) showed no negative effect on the antitu-
bercular activity. Thus, we moved the phenyl ring
(fragment A) to the double bond position between
the quinoline and basic amino groups, but kept frag-
ment C attached to the 2-position of the quinoline.
The synthesis of 3-aromatic analogues 30 is shown in
Scheme 5. The synthesis of key substituted quinoline
intermediates 26 started from substituted quinoline
25. The reaction of 25 and N-iodosuccinimide gave
3-iodoquinoline 26, which was then treated with
meta-chloroperoxybenzoic acid (mCPBA) to produce
27, and chlorinated with phosphoryl chloride to give
2-chloro-3-iodoquinoline 28. Target compounds 30
were prepared via Suzuki–Miyaura coupling of com-
pound 28 with the corresponding substituted boric
acid or boronic acid pinacol cyclic ester to obtain
29.[27] Subsequently, the chloro moiety was ex-
changed with benzyl alcohol, aromatic alcohol,
phenol, thiophenol, or aromatic amine by a nucleo-
philic substitution to obtain 30.
Table 2. In vitro antitubercular activity of series 2 compounds.[a]
Compd R1 R2 MIC CC50
[b]
mgmL@1 mm mgmL@1 mm
16a H 7.7 17.0 14 30.9
16b H 6.4 13.7 12 25.7
16c H 3.8 8.9 8.9 20.8
16d Br 4.2 8.3 30 59.3
16e Br >32 >67.5 >64 >135.0
16 f Br 2.0 4.0 9.2 18.4
[a] Reference compound: bedaquiline MIC=0.060 mgmL@1 (0.1 mm). [b] Concentration
at which the growth of Vero cells is inhibited by 50%.
Scheme 4. Synthesis of series 3 compounds. Reagents and conditions : (a) methylmagnesium iodide or phenylmagnesium bromide, THF, 0 8C, 76.4–78.5%;
b) Dess–Martin periodinane, CH2Cl2, RT, 92.7–95.5%; c) 1-naphthol, K2CO3, DMSO, 100 8C, 86.9–92.9%; d) hydroxylamine hydrochloride, Et3N, EtOH, RT, 84.6%;
e) 2-dimethylaminoethyl chloride hydrochloride, NaH, THF, 66.8%; f) (3-(dimethylamino)propyl)magnesium chloride, 95.7%; g) HCl/EtOH, reflux, 72.7%.
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In total, 14 compounds were synthesized for series 4 (30a–
30n ; Table 4), all of which contain no more chiral centers. Intri-
guingly, series 4 compounds were generally potent against my-
cobacteria with MIC values of ~1 mgmL@1, whereas
their CC50 values were 10-fold higher on average.
Comparison of the structures and antitubercular ac-
tivities of series 4 compounds shows that the length
of the terminal amine chain can be 1–2 carbons
(compounds 30a, 30b) while retaining antitubercular
activity. Further, the presence of the terminal basic ni-
trogen atom was essential to sustain the antitubercu-
lar activity (compounds 30h, 30m), whereas the
bromo group was not (compounds 30e, 30 f).
Second round of optimization
Based on the results obtained from series 4, we ex-
plored the effect of 2-aryl substituents and the
spacer length of the terminal amine group in our
new scaffold of 2-aryl-3-(dimethylamino-substituted)phenylqui-
noline on antitubercular activity (Figure 2).
In the first group of compounds (Table 5), we investigated
the position at which the basic nitrogen containing side chain
was attached to the phenyl ring as well as the lateral chain
length. We assembled a small library of 6-bromo-2-((naphth-1-
yl)methyl)oxy-3-substituted phenylquinoline analogues (32).
The synthetic route is outlined in Scheme 6. The antitubercular
screening assay showed that : 1) the para-substituted N,N-di-
methylaminomethylphenyl ring has the most potent antituber-
cular activity for this scaffold, and 2) the terminal nitrogen
atom is necessary for antitubercular activity. Other substituents
decreased the antitubercular activity of this scaffold significant-
ly. Compounds 32a, 32d, and 32e showed antitubercular ac-
tivities (MIC) of 0.43, 0.47, and 0.44 mgmL@1, and cytotoxicity
(CC50) against mammalian cells of 13, 12, and 3.9 mgmL
@1, re-
spectively.
Next, we substituted the naphthalen-1-ylmethanol ring with
various aryl groups that have different physicochemical proper-
ties, while keeping 4-(N,N-dimethylaminomethyl)phenyl group
as the 3-substituent. A small group of analogues 34 were syn-
thesized (Scheme 7). Antitubercular screening showed activity
of several derivatives with MIC~0.4 mgmL@1 (Table 6). The aryl-
methyloxy group at C2 of the quinolone was substituted with
a variety of aromatic groups having different physicochemical
properties, such as a para-chlorophen-1-ylmethanol ring (34 i,
MIC=0.55 mgmL@1) or a pyridin-4-ylmethanol ring (34m,
Scheme 5. Synthesis of series 4 compounds. Reagents and conditions : a) N-iodosuccini-
mide, AcOH, 100 8C, 28 h, 47.4–46.9%; b) mCPBA, CHCl3, 3 h, RT, 90.6–92.7%; c) POCl3,
CHCl3, 3 h, reflux, 72.9–85.7%; d) 4-(dimethylamino)methylphenylboronic acid, Pd(PPh3)4,
Na2CO3, toluene/H2O, 14 h, 76.3–91.5%; e) benzyl alcohol/phenol/thiophenol, NaH, THF,
RT, 6 h, 68.0–99.3%.
Table 3. In vitro antitubercular activity of series 3 compounds.[a]
Compd R MIC CC50
[b]
mgmL@1 mm mgmL@1 mm
22 4.0 10.0 11 27.5
23 2.0 4.3 4.4 9.5
24 1.8 4.1 10 22.5
[a] Reference compound: bedaquiline MIC=0.060 mgmL@1 (0.1 mm).
[b] Concentration at which the growth of Vero cells is inhibited by 50%.
Figure 2. Scheme for the second round of compound optimization. Starting from bedaquiline, both chiral carbon atoms in the first round of optimization
were removed, and a new scaffold of 2-oxy-3-phenyl-6-bromoquinoline with potent anti-TB activity was obtained. In the second round of optimization, the
substituents of this new scaffold were changed to improve the anti-TB activity of these new compounds.
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Table 4. In vitro antitubercular activity of series 4 compounds.[a]
Compd R1 R2 R3 MIC CC50
[b]
mgmL@1 mm mgmL@1 mm
30a Br 1.0 2.0 10 20.1
30b Br 2.0 3.9 3.8 7.4
30c Br 1.8 3.5 12 23.4
30d Br 1.6 3.3 25 51.9
30e OMe 1.8 4.0 12 26.7
30 f H 2.0 4.9 15 37.1
30g H >32 76.5 >64 >153.1
30h Br >32 >75.1 >64 >150.2
30 i Br >32 >73.7 >64 >147.5
30 j Br 1.6 3.3 4.4 9.2
30k Br 1.9 4.0 11 23.6
30 l Br 1.0 2.2 11 23.6
30m Br >32 >63.8 >64 >127.8
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MIC=0.43 mgmL@1). These substituents maintain the antituber-
cular activity, and may provide a method for optimizing the
physicochemical properties of the final compounds.
Inhibition of ATP synthesis activity by selected compounds
in mycobacteria
The design of the new antimycobacterial lead compounds was
inspired by bedaquiline, which is known to inhibit mycobacte-
rial ATP synthase with an IC50 value in the low nanomolar
range (Supporting Information Figure S1).[14] To determine if
the new compounds share this property, nine candidates with
MIC values in the sub-microgram per mL range were selected
(Table S1) and tested for their ability to inhibit the ATP synthe-
sis activity of Mycobacterium phlei inverted membrane vesicles
(IMVs) (Figure 3A). A concentration range of 0–100 mm was as-
sayed for each compound. The calculated activities were used
to determine an IC50 value for each of the candidates (Fig-
ure 3B). Six of the compounds (34m, 32h, 34a, 34 f, 32e, and
32o) inhibited ATP synthesis with IC50 values between 20 and
40 mm (Figure S2). One candidate (34 i) showed a slight inhibi-
tory effect; however, the IC50 value could not be calculated
due to the low solubility of the compound. The best
candidate was compound 34m with an IC50 value of
20.3:1 mm (Figure 3C) and an improved logP of 5.55
(Table S1), which may also be beneficial from a phar-
macokinetic point of view and which may help de-
crease some of the adverse side effects of bedaqui-
line.[8, 12] Remarkably, two compounds (32d and 32p)
did not affect ATP synthesis at all, while still display-
ing potent antimycobacterial activity (MIC90 : 0.47 and
0.51 mgmL@1, respectively ; Figure S2). As a control, in-
hibition by bedaquiline was assayed, exhibiting an
IC50 value <10 nm (Figure S1).
All seven tested compounds, which inhibited ATP
synthesis activity, share a structural feature with be-
daquiline, that is, the presence of a dimethylamino
(DMA) moiety. This structural part of bedaquiline rep-
resents the most important structural feature in the
interaction with the ATP synthase c-ring and is hence
a decisive element of the molecule’s inhibitory
power.[14] In the lead compounds described herein,
the DMA moieties are all attached to longer aryl side
chains than the ethyl chain present in bedaquiline. Therefore,
the subtle but exact structural placement of this critical moiety
is impaired, which explains the higher IC50 values measured for
these derivatives. In agreement with that notion are the two
candidates (32d and 32p), which show no influence on ATP
synthesis activity and lack this structural element completely.
The fact that these compounds still show specific killing activi-
ty on mycobacteria (Table S1) implies that they target and
affect other cellular processes or proteins in mycobacterial
cells. Future work needs to be carried out to identify these po-
tentially interesting targets.
In vitro anti-TB activities against drug-resistant clinical
isolates of M. tuberculosis
To further explore the effect of selected compounds on drug-
resistant clinical isolates of M. tuberculosis and compare it with
the effect on the drug-sensitive H37Rv strain, we performed
MIC determinations with two representative compounds that
showed ATP synthesis inhibitory activity (34m and 32e) and
two candidates that showed only marginal and no effect on
the ATP synthase, 34 i and 32d, respectively (Figure 3C). The in
Table 4. (Continued)
Compd R1 R2 R3 MIC CC50
[b]
mgmL@1 mm mgmL@1 mm
30n Br >32 >67.5 3.9 8.2
[a] Reference compound: bedaquiline MIC=0.060 mgmL@1 (0.1 mm). [b] Concentration at which the growth of Vero cells is inhibited by 50%.
Scheme 6. Synthesis of compound 32. Reagents and conditions : a) 1-naphthalenemetha-
nol, NaH, THF, RT, 6 h, 93.4%; b) for boric acid: Pd(PPh3)4, Na2CO3, toluene/H2O, 14 h, for
boronic acid pinacol cyclic ester: Pd(dppf)Cl2·CH2Cl2, Na2CO3, toluene/H2O, 14 h, 41.4–
86.8%.
Scheme 7. Synthesis of compound 34. Reagents and conditions : a) (4-((dimethylamino)-
methyl)phenyl)boronic acid, Pd(PPh3)4, Na2CO3, toluene/H2O, 14 h, 81.5–85.8%; b) NaH,
THF, RT, 6 h, 34.4–91.3%.
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vitro inhibitory activities of these four compounds
were screened against two drug-resistant clinical iso-
lates (isolates 12513 and 6133), which are both resist-
ant to isoniazid (INH) and rifampicin (RFP).[28] The MIC
values against the drug-sensitive H37Rv strain of
M. tuberculosis were also determined again (Table 7).
Compounds 34m and 32e exhibited similar MIC
values for both the drug-resistant and drug-sensitive
strains. Interestingly, for compound 34 i that had only
marginal effects on ATP synthesis, the MICs for the
drug-resistant strains 6133 and 12153 were 5.4- and
7.9-fold higher. A similar effect was observed for
compound 32d, which had no measureable impact
on ATP synthesis : the MIC was found to be 7.4-fold
higher for strain 6133 than for the drug-sensitive
H37Rv strain. The measured effects for 34 i and 32d
indicate that these compounds target alternative
sites or processes in the mycobacterial cell ; these re-
sults encourage future work to identify these novel
targets and to validate them in greater detail as po-
tential new sites for mycobacterial inhibitors.
Conclusions
In this study we describe the chemical simplification
of bedaquiline, while largely retaining the potent an-
titubercular activity. Inspired by the SAR of bedaqui-
line, we designed a set of new lead compounds
using a fragment-based approach. The bedaquiline
molecule was first split into its various functional
groups and recombined in a way that decreased or
completely removed the initial stereochemical com-
plexity. The approach promises to significantly de-
crease production costs and make it accessible for
a broader variety of chemical laboratories and clinics.
Initially, four series of compounds were designed,
synthesized, and evaluated for their antitubercular
activity. Among the initial four series of compounds,
series 4, incorporating a 2-aryl moiety and a 3-(4-
(N,N-dimethylamino)methyl)phenyl group, was found
to contain the most potent analogues with MIC
values <1 mgmL@1. Further optimization of this scaf-
fold, modifying the C2 and C6 positions of the quino-
line, yielded several potent inhibitors with MIC<
0.6 mgmL@1. The most potent candidates were select-
ed and assayed for their capacity to inhibit ATP syn-
thesis activity in mycobacterial membranes. Our bio-
chemical analysis reveals that some of the newly syn-
thesized compounds showed a direct impact on my-
cobacterial ATP synthesis, with IC50 values between
20 and 40 mm, while others did not affect ATP synthe-
sis itself. The latter compounds are promising new
candidates that are able to target other cellular pro-
cesses in mycobacterial cells. This study provides the
basis for the development of novel, chemically sim-
plified, low-cost bedaquiline derivatives to fight
drug-resistant M. tuberculosis strains.
Table 5. In vitro antitubercular activity of compounds from the second round of opti-
mization.[a]
Compd R MIC CC50
[b]
mgmL@1 mm mgmL@1 mm
32a 0.43 0.87 13 26.1
32b 1.9 3.7 6.3 12.3
32c 1.7 3.2 4.1 7.6
32d 0.47 0.87 12 22.3
32e 0.44 0.73 3.9 6.6
32 f 2.2 3.9 4.8 8.6
32g 1.5 2.3 >64 >101.9
32h 0.61 1.0 4.6 7.5
32 i 3.4 6.3 3.8 7.0
32 j 10 15.6 36 56.3
32k 0.73 1.2 53 87.9
32 l 0.84 1.6 40 77.7
32m 1.4 2.7 14 27.1
32n 0.79 1.5 3.7 7.0
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Experimental Section
Chemistry : All reagents and anhydrous solvents are commercially
available and were used without further purification. Temperatures
are given in degrees Celsius (8C). NMR spectra were recorded on
Bruker AVIIIHD spectrometers using TMS as internal standard.
Chemical shifts (d) are reported in ppm, and coupling constants (J)
are given in hertz (Hz). The following multiplicity abbreviations are
used: (s) singlet, (d) doublet, (t) triplet, (q) quartet, (m) multiplet,
and (br) broad. ESI-HRMS data were measured on a Thermo Exac-
tive Orbitrap Plus spectrometer. All reactions were monitored by
TLC. Column chromatography was carried out with silica gel (200–
300 mesh size). Flash column chromatography was performed on
a Biotage Isolera One instrument. Purity was determined by LC–MS
and NMR spectroscopy. All final compounds are >95% pure. See
the Supporting Information for detailed synthesis and characteriza-
tion of all intermediates and final compounds.
6-Bromo-3-(4-((dimethylamino)methyl)phenyl)-2-(naphthalen-1-
ylmethoxy)quinoline (32a): A mixture of 6-bromo-3-iodo-2-(naph-
thalen-1-ylmethoxy)quinoline 31 (100 mg, 0.20 mmol), tetrakis(tri-
phenylphosphine)palladium (12 mg, 0.01 mmol), Na2CO3 (43 mg,
0.41 mmol) and 3-((dimethylamino)methyl)phenylboronic acid
(39 mg, 0.22 mmol) in the mixture of toluene (4 mL) and water
(2 mL) was stirred at 80 8C for 10 h. Water (10 mL) was added and
the mixture was extracted with CH2Cl2 (3V10 mL), dried
with Na2SO4 and concentrated. The residue was purified
by flash column chromatography with petroleum ether/
ethyl acetate/triethylamine (40:15:1) to afford 32a as
a white solid (87 mg, 87.3%); mp: 85–86 8C. 1H NMR
(400 MHz, [D6]acetone): d=8.23 (d, J=8.2 Hz, 1H), 8.18
(s, 1H), 8.11 (s, 1H), 7.94 (d, J=7.8 Hz, 1H), 7.88 (d, J=
8.4 Hz, 1H), 7.85 (d, J=8.9 Hz, 1H), 7.78 (dd, J=8.8,
1.6 Hz, 1H), 7.72 (d, J=6.9 Hz, 1H), 7.61–7.56 (m, 3H),
7.54 (t, J=6.8 Hz, 1H), 7.46 (t, J=7.6 Hz, 1H), 7.29 (d, J=
7.9 Hz, 2H), 6.07 (s, 2H), 3.38 (s, 2H), 2.17 ppm (s, 6H);
13C NMR (100 MHz, [D6]acetone): d=160.22, 145.21,
140.31, 138.10, 135.47, 134.74, 133.66, 133.26, 132.68,
130.60, 130.07, 129.66, 129.64, 129.43, 129.33, 128.30,
128.11, 128.00, 127.13, 126.73, 126.15, 124.94, 117.89,
67.02, 64.33, 45.56 ppm; HRMS (ESI-TOF, m/z): calcd for
C29H26ON2Br [M+H]
+ 497.1223, found: 497.1223.
6-Bromo-3-(4-(4-methylpiperazin-1-yl)phenyl)-2-(naph-
thalen-1-ylmethoxy)quinoline (32d): The procedure
used to synthesize 32a was repeated using 31 and (4-(4-
methylpiperazin-1-yl)phenyl)boronic acid to afford com-
pound 32d as a white solid in 79.1% yield; mp: 132–
133 8C. 1H NMR (400 MHz, [D6]acetone): d=8.26 (d, J=
8.5 Hz, 1H), 8.14 (s, 1H), 8.10 (d, J=2.2 Hz, 1H), 7.96 (d,
J=7.6 Hz, 1H), 7.91 (d, J=8.3 Hz, 1H), 7.84 (d, J=8.9 Hz,
1H), 7.80–7.71 (m, 2H), 7.65–7.59 (m, 1H), 7.59–7.52 (m,
3H), 7.49 (dd, J=8.2, 7.1 Hz, 1H), 6.95–6.85 (m, 2H), 6.09
(s, 2H), 3.24–3.13 (m, 4H),2.51–2.41 (m, 4H), 2.24 ppm (s,
3H); 13C NMR (100 MHz, [D6]acetone): d=160.43, 152.09,
144.80, 136.96, 134.77, 133.80, 132.80, 132.73, 131.02,
130.39, 129.62, 129.61, 129.46, 128.44, 128.25, 128.15,
127.19, 126.81, 126.75, 126.22, 124.95, 117.79, 115.59,
66.92, 55.79, 48.99, 46.39 ppm; HRMS (ESI-TOF, m/z):
calcd for C31H29ON3Br [M+H]
+ 538.1485, found
538.1482.
6-Bromo-3-(4-((4-(2-(dimethylamino)ethyl)piperazin-1-
yl)methyl)phenyl)-2-(naphthalen-1-ylmethoxy)quino-
line (32h): The procedure used to synthesize 32a was
repeated using 31 and (4-((4-(2-(dimethylamino)ethyl)pi-
perazin-1-yl)methyl)phenyl)boronic acid to afford compound 32h
as a yellow wax-like solid in 67.2% yield; mp: 95–96 8C. 1H NMR
(400 MHz, [D6]acetone): d=8.24 (d, J=8.2 Hz, 1H), 8.20 (s, 1H),
8.12 (s, 1H), 7.95 (d, J=7.8 Hz, 1H), 7.89 (d, J=8.3 Hz, 1H), 7.86 (d,
J=9.0 Hz, 1H), 7.79 (d, J=8.9 Hz, 1H), 7.73 (d, J=6.9 Hz, 1H),
7.66–7.50 (m, 4H), 7.47 (t, J=7.7 Hz, 1H), 7.30 (d, J=7.9 Hz, 2H),
6.08 (s, 2H), 3.45 (s, 2H), 2.63–2.27 (m, 12H), 2.16 ppm (s, 6H);
13C NMR (150 MHz, [D6]acetone): d=160.26, 145.24, 139.71, 138.14,
135.50, 134.77, 133.68, 133.30, 132.71, 130.62, 130.11, 129.69,
129.68, 129.45, 128.35, 128.15, 128.03, 127.15, 126.76, 126.18,
124.99, 117.92, 67.05, 63.11, 58.02, 57.42, 54.47, 54.03, 46.09 ppm;
HRMS (ESI-TOF, m/z): calcd for C35H38ON4
81Br [M+H]+ 611.2203,
found 611.2185.
6-Bromo-3-(4-(((3s,5s,7s)-adamantan-1-ylamino)methyl)phenyl)-
2-(naphthalen-1-ylmethoxy)quinoline (32k): The procedure used
to synthesize 32a was repeated using 31 and (4-(((3s,5s,7s)-ada-
mantan-1-ylamino)methyl)phenyl)boronic acid to afford compound
32k as a yellow solid in 55.1% yield; mp: 72–73 8C. 1H NMR
(400 MHz, [D6]acetone): d=8.25 (d, J=8.1 Hz, 1H), 8.18 (s, 1H),
8.12 (d, J=1.6 Hz, 1H), 7.95 (d, J=8.0 Hz, 1H), 7.90 (d, J=8.4 Hz,
1H), 7.86 (d, J=8.9 Hz, 1H), 7.78 (dd, J=8.8, 1.8 Hz, 1H), 7.74 (d,
J=6.8 Hz, 1H), 7.61 (t, J=7.6 Hz, 1H), 7.58–7.51 (m, 3H), 7.48 (t,
J=7.6 Hz, 1H), 7.34 (d, J=7.9 Hz, 2H), 6.08 (s, 2H), 3.74 (s, 2H), 2.77
Table 5. (Continued)
Compd R MIC CC50
[b]
mgmL@1 mm mgmL@1 mm
32o 0.67 1.3 12 22.7
32p 0.51 0.94 13 24.1
32q 1.1 2.1 17 32.7
32r 3.1 5.7 >64 >118.7
32s >32 >62.3 >64 >124.5
32t >32 >60.9 >64 >121.9
32u >32 >62.9 >64 >125.7
32v >32 >59.8 44 82.2
[a] Reference compound: bedaquiline MIC=0.060 mgmL@1 (0.1 mm). [b] Concentration
at which the growth of Vero cells is inhibited by 50%.
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(br s, 1H), 1.92–1.45 ppm (m, 15H); 13C NMR (150 MHz,
[D6]acetone): d=160.33, 145.20, 143.69, 138.07, 134.90,
134.79, 133.70, 133.24, 132.76, 130.60, 129.97, 129.70,
129.69, 129.47, 128.64, 128.50, 128.26, 128.06, 127.20,
126.78, 126.21, 124.98, 117.90, 67.07, 51.12, 45.09, 43.65,
37.56, 30.59 ppm; HRMS (ESI-TOF, m/z): calcd for
C37H36ON2
81Br [M+H]+ 605.1985, found 605.1.992
6-Bromo-3-(4-((dimethylamino)methyl)-3-fluorophen-
yl)-2-(naphthalen-1-ylmethoxy)quinoline (32 l): The
procedure used to synthesize 32b was repeated using
31 and (4-((dimethylamino)methyl)-3-fluorophenyl)bor-
onic acid pinacol ester to afford compound 32 l as
a white solid in 71.4% yield; mp: 106–107 8C. 1H NMR
(400 MHz, [D6]acetone): d=8.30–8.21 (m, 2H), 8.14 (s,
1H), 7.96 (d, J=7.8 Hz, 1H), 7.91 (d, J=8.3 Hz, 1H), 7.88
(d, J=9.2 Hz, 1H), 7.82 (d, J=8.9 Hz, 1H), 7.75 (d, J=
6.9 Hz, 1H), 7.60 (t, J=6.9 Hz, 1H), 7.55 (t, J=6.9 Hz, 1H),
7.51–7.44 (m, 2H), 7.43–7.34 (m, 2H), 6.10 (s, 2H), 3.44 (s,
2H), 2.19 ppm (s, 6H); 13C NMR (150 MHz, [D6]acetone):
d=162.47, 160.85, 159.97, 145.43, 138.56, 137.69, 137.63,
134.80, 133.65, 133.56, 132.76, 131.95, 131.92, 130.77,
129.79, 129.72, 129.48, 128.33, 127.88, 127.26, 126.97,
126.96, 126.79, 126.53, 126.43, 126.18, 125.88, 125.86,
124.94, 118.05, 117.01, 116.85, 67.20, 56.63, 56.62,
45.45 ppm; HRMS (ESI-TOF, m/z): calcd for C29H25ON2
81BrF
[M+H]+ 517.1108, found 517.1117.
6-Bromo-3-(4-((dimethylamino)methyl)-3-methoxy-
phenyl)-2-(naphthalen-1-ylmethoxy)quinoline (32n):
The procedure used to synthesize 32b was repeated
using 31 and (4-((dimethylamino)methyl)-3-methoxyphe-
nyl)boronic acid pinacol ester to afford compound 32n
as a white solid in 78.5% yield; mp: 106–107 8C. 1H NMR
(600 MHz, [D6]acetone): d=8.26 (s, 1H), 8.23 (d, J=
8.3 Hz, 1H), 8.14 (d, J=2.2 Hz, 1H), 7.97 (d, J=7.5 Hz,
1H), 7.93 (d, J=8.3 Hz, 1H), 7.88 (d, J=8.8 Hz, 1H), 7.80
(dd, J=8.8, 2.3 Hz, 1H), 7.75 (d, J=6.8 Hz, 1H), 7.62–7.57
(m, 1H), 7.57–7.53 (m, 1H), 7.49 (dd, J=8.2, 7.0 Hz, 1H),
7.34 (d, J=7.6 Hz, 1H), 7.22–7.15 (m, 2H), 6.06 (s, 2H),
3.35 (s, 2H), 3.27 (s, 3H), 2.16 ppm (s, 6H); 13C NMR
(150 MHz, [D6]acetone): d=160.26, 157.97, 145.24,
138.11, 136.43, 134.82, 133.66, 133.33, 132.91, 130.67,
130.46, 129.90, 129.69, 129.53, 128.70, 128.21, 128.07,
128.04, 127.44, 126.80, 126.27, 124.92, 121.98, 117.92,
112.64, 67.25, 57.55, 55.24, 45.74 ppm; HRMS (ESI-TOF,
m/z): calcd for C30H28O2N2Br [M+H]
+ 527.1329, found
527.1323.
6-Bromo-3-(4-((dimethylamino)methyl)-2-methoxy-
phenyl)-2-(naphthalen-1-ylmethoxy)quinoline (32o):
The procedure used to synthesize 32b was repeated
using 31 and (4-((dimethylamino)methyl)-2-methoxyphe-
nyl)boronic acid pinacol ester to afford compound 32o
as a yellow solid in 71.8% yield; mp: 65–66 8C. 1H NMR
(600 MHz, [D6]acetone): d=8.12 (dd, J=8.0, 1.0 Hz, 1H),
8.08 (d, J=2.2 Hz, 1H), 8.04 (s, 1H), 7.91 (dd, J=7.5,
1.9 Hz, 1H), 7.85 (d, J=6.1 Hz, 1H), 7.84 (d, J=6.7 Hz,
1H), 7.77 (dd, J=8.9, 2.3 Hz, 1H), 7.63 (dd, J=6.9, 0.6 Hz,
1H), 7.57–7.49 (m, 2H), 7.42 (dd, J=8.2, 7.1 Hz, 1H), 7.23
(d, J=7.5 Hz, 1H), 6.98 (s, 1H), 6.92–6.86 (m, 1H), 3.56 (s,
3H), 3.39 (s, 2H), 2.19 ppm (s, 6H); 13C NMR (150 MHz,
[D6]acetone): d=161.08, 158.17, 145.43, 142.42, 138.88,
134.66, 133.89, 133.09, 132.58, 131.46, 130.44, 129.72,
129.36, 129.33, 127.76, 127.42, 127.06, 126.62, 126.50,
Table 6. In vitro antitubercular activity of compounds from the second round of opti-
mization.[a]
Compd R1 R2 MIC CC50
[b]
mgmL@1 mm mgmL@1 mm
34a H 0.62 1.5 4.0 9.6
34b Br 1.6 3.7 11 25.4
34c Br 2.5 5.6 7.8 17.4
34d Br 2.0 4.3 12 26.0
34e Br 0.81 1.7 6.2 12.9
34 f Br 0.58 1.2 4.4 9.2
34g Br 5.2 10.9 5.6 11.7
34h Br 0.72 1.5 7.4 15.9
34 i Br 0.55 1.1 11 22.9
34 j Br 1.5 3.1 4.2 8.7
34k Br 0.89 1.7 14 26.8
34 l Br 0.79 1.5 5.0 9.3
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126.12, 124.88, 124.83, 121.30, 117.64, 111.83, 66.56,
64.71, 55.65, 45.62 ppm; HRMS (ESI-TOF, m/z): calcd for
C30H28O2N2Br [M+H]
+ 527.1329, found 527.1325.
6-Bromo-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-2-
(naphthalen-1-ylmethoxy)quinoline (32p): The proce-
dure used to synthesize 32b was repeated using 31 and
(6-(4-methylpiperazin-1-yl)pyridin-3-yl)boronic acid pina-
col ester to afford compound 32p as a white solid in
81.2% yield; mp: 130–131 8C. 1H NMR (400 MHz,
[D6]acetone): d=8.42 (d, J=1.8 Hz, 1H), 8.23 (d, J=
8.2 Hz, 1H), 8.18 (s, 1H), 8.10 (d, J=1.8 Hz, 1H), 7.96 (d,
J=7.8 Hz, 1H), 7.91 (d, J=8.3 Hz, 1H), 7.87–7.79 (m, 2H),
7.79–7.70 (m, 2H), 7.64–7.52 (m, 2H), 7.49 (t, J=7.6 Hz,
1H), 6.70 (d, J=8.9 Hz, 1H), 6.09 (s, 2H), 3.53 (t, J=5.0 Hz,
4H), 2.39 (t, J=5.0 Hz, 4H), 2.23 ppm (s, 3H); 13C NMR
(150 MHz, [D6]acetone): d=160.38, 159.64, 149.00, 144.96,
139.05, 136.75, 134.79, 133.67, 133.01, 132.78, 130.44,
129.76, 129.66, 129.50, 128.32, 128.18, 127.28, 126.79,
126.24, 125.84, 124.85, 121.44, 117.92, 106.54, 67.06, 55.58,
46.43, 45.55 ppm; HRMS (ESI-TOF, m/z): calcd for
C30H28
81BrN4O [M+H]
+ 541.1421, found 541.1427.
3-(4-((Dimethylamino)methyl)phenyl)-2-(naphthalen-1-
ylmethoxy)quinoline (34a): To a solution of 2-chloro-3-
(4-((dimethylamino)methyl)phenyl)quinoline (100 mg,
Table 6. (Continued)
Compd R1 R2 MIC CC50
[b]
mgmL@1 mm mgmL@1 mm
34m Br 0.43 0.95 3.0 6.7
34n Br 0.71 1.5 9.7 20.9
34o Br 1.6 3.9 12 29.4
34p Br 5.9 15.9 17 45.8
[a] Reference compound: bedaquiline MIC=0.060 mgmL@1 (0.1 mm). [b] Concentration
at which the growth of Vero cells is inhibited by 50%.
Figure 3. Inhibition of ATP synthesis in mycobacteria by selected lead compounds. The top nine candidates, selected by their MIC values, were tested for
their ATP synthesis inhibitory activity using Mycobacterium phlei inverted membrane vesicles. The corresponding IC50 values were determined in a concentra-
tion-dependent series of inhibition measurements. A) ATP synthesis activities were recorded using a luminescence-based activity assay.[14] The increasing lumi-
nescence signal, indicating continuous ATP synthesis at various concentrations (shown in different colors) of compound 34m, is shown exemplarily. As a con-
trol, the uncoupler carbonyl cyanide m-chlorophenyl hydrazone (CCCP) is plotted (purple trace). B) Concentration-dependent inhibition of ATP synthesis and
determination of IC50 for 34m. The rates for ATP synthesis were calculated and plotted versus the concentration of compound 34m to determine the concen-
tration required to inhibit 50% of remaining activity (IC50). Error bars represent the standard deviation of at least three biological replicates. C) IC50 values de-
termined for the tested compounds. Whereas six compounds showed inhibition of ATP synthesis activity with IC50 values between 20 and 40 mm (34m, 32h,
34a, 34 f, 32e, and 32o) and one >66 mm (34 i), two compounds (32d and 32p) showed no measurable effect up to 100 mm.
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0.34 mmol) and 1-naphthalenemethanol (68 mg, 0.43 mmol) in
4 mL DMF was added Cs2CO3 (140 mg, 0.43 mmol). After stirring at
80 8C for 8 h, water (20 mL) was added, and the mixture was ex-
tracted with CH2Cl2 (3V10 mL), dried with Na2SO4 and concentrat-
ed. The residue was purified by flash column chromatography with
petroleum ether/ethyl acetate/triethylamine (40:15:1) to afford
34a as a white solid (128.9 mg, 91.2%); mp: 93–95 8C. 1H NMR
(600 MHz, [D6]acetone): d=8.25 (d, J=8.4 Hz, 1H), 8.21 (s, 1H),
7.98–7.89 (m, 3H), 7.88 (d, J=8.3 Hz, 1H), 7.74 (d, J=6.9 Hz, 1H),
7.69 (t, J=7.6 Hz, 1H), 7.65–7.58 (m, 3H), 7.55 (t, J=7.4 Hz, 1H),
7.46 (t, J=7.6 Hz, 2H), 7.29 (d, J=7.9 Hz, 2H), 6.09 (s, 2H), 3.39 (s,
2H), 2.17 ppm (s, 6H); 13C NMR (150 MHz, [D6]acetone): d=159.80,
146.56, 139.94, 139.07, 136.01, 134.76, 133.94, 132.73, 130.31,
130.09, 129.56, 129.43, 129.32, 128.62, 128.04, 127.65, 127.22,
127.11, 126.72, 126.70, 126.18, 125.30, 124.99, 66.77, 64.35,
45.55 ppm; HRMS (ESI-TOF, m/z): calcd for C29H27N2O [M+H]
+
419.2118, found 419.2110.
6-Bromo-3-(4-((dimethylamino)methyl)phenyl)-2-((2-methoxy-
benzyl)oxy)quinoline (34e): The procedure used to synthesize
34a was repeated using 33a and 2-methoxybenzyl alcohol to
afford compound 34e as a yellow wax-like solid in 81.5% yield;
mp: 96–97 8C. 1H NMR (600 MHz, [D6]acetone): d=8.20 (s, 1H), 8.11
(d, J=2.2 Hz, 1H), 7.81 (d, J=8.8 Hz, 1H), 7.76 (dd, J=8.9, 2.2 Hz,
1H), 7.73–7.64 (m, 2H), 7.44 (dd, J=7.5, 1.4 Hz, 1H), 7.40 (d, J=
8.2 Hz, 2H), 7.29 (td, J=8.2, 1.7 Hz, 1H), 7.03 (d, J=8.1 Hz, 1H),
6.90 (td, J=7.4, 0.7 Hz, 1H), 5.60 (s, 2H), 3.91 (s, 3H), 3.44 (s, 2H),
2.21 ppm (s, 6H); 13C NMR (150 MHz, [D6]acetone): d=160.48,
158.37, 145.31, 140.42, 137.92, 135.64, 133.20, 130.59, 130.14,
129.93, 129.87, 129.64, 129.41, 128.28, 127.97, 126.10, 121.04,
117.77, 111.32, 64.49, 64.44, 55.81, 45.61 ppm; HRMS (ESI-TOF, m/z):
calcd for C26H26BrN2O2 [M+H]
+ 477.1172, found 477.1166.
6-Bromo-3-(4-((dimethylamino)methyl)phenyl)-2-((3-methoxy-
benzyl)oxy)quinoline (34 f): The procedure used to synthesize
34a was repeated using 33a and 3-methoxybenzyl alcohol to
afford compound 34 f as a colorless wax-like solid in 92.4% yield;
mp: 52–53 8C. 1H NMR (600 MHz, [D6]acetone): d=8.20 (s, 1H), 8.11
(d, J=2.1 Hz, 1H), 7.80 (d, J=8.8 Hz, 1H), 7.76 (dd, J=8.9, 2.2 Hz,
1H), 7.69 (d, J=8.2 Hz, 2H), 7.42 (d, J=8.2 Hz, 2H), 7.26 (t, J=
7.9 Hz, 1H), 7.09 (d, J=1.7 Hz, 1H), 7.06 (d, J=7.5 Hz, 1H), 6.84
(dd, J=8.1, 2.4 Hz, 1H), 5.58 (s, 2H), 3.76 (s, 3H), 3.45 (s, 2H),
2.22 ppm (s, 6H); 13C NMR (150 MHz, [D6]acetone): d=160.75,
160.22, 145.22, 140.45, 139.79, 138.06, 135.60, 133.26, 130.60,
130.20, 130.14, 129.61, 129.46, 128.24, 127.98, 120.55, 117.88,
114.23, 113.68, 68.46, 64.42, 55.45, 45.61 ppm; HRMS (ESI-TOF, m/z):
calcd for C26H26BrN2O2 [M+H]
+ 477.1172, found 477.1167.
6-Bromo-3-(4-((dimethylamino)methyl)phenyl)-2-((3-fluoro-
benzyl)oxy)quinoline (34h): The procedure used to synthesize
34a was repeated using 33a and 3-fluorobenzyl alcohol to afford
compound 34h as a yellow solid in 85.4% yield; mp: 82–83 8C.
1H NMR (600 MHz, [D6]acetone): d=8.21 (s, 1H), 8.12 (d, J=2.1 Hz,
1H), 7.79 (d, J=8.8 Hz, 1H), 7.76 (dd, J=8.9, 2.1 Hz, 1H), 7.71–7.65
(m, 2H), 7.43 (d, J=8.3 Hz, 2H), 7.39 (td, J=7.9, 5.9 Hz, 1H), 7.33
(d, J=7.7 Hz, 1H), 7.30–7.24 (m, 1H), 7.09–7.01 (m, 1H), 5.62 (s,
2H), 3.46 (s, 2H), 2.22 ppm (s, 6H); 13C NMR (150 MHz, [D6]acetone):
d=164.48, 162.86, 160.04, 145.14, 141.25, 141.20, 140.52, 138.17,
135.50, 133.33, 131.10, 131.04, 130.63, 130.13, 129.62, 129.48,
128.21, 128.04, 124.33, 124.31, 118.00, 115.27, 115.19, 115.12,
115.05, 67.79, 67.78, 64.42, 45.60 ppm; HRMS (ESI-TOF, m/z): calcd
for C25H23BrFN2O [M+H]
+ 465.0972, found 465.0974.
6-Bromo-2-((4-chlorobenzyl)oxy)-3-(4-((dimethylamino)methyl)-
phenyl)quinoline (34 i): The procedure used to synthesize 34a was
repeated using 33a and 4-chlorobenzyl alcohol to afford com-
pound 34 i as a yellow solid in 82.4% yield; mp: 120–121 8C.
1H NMR (600 MHz, [D6]acetone): d=8.21 (s, 1H), 8.12 (d, J=2.0 Hz,
1H), 7.79 (d, J=8.8 Hz, 1H), 7.76 (dd, J=8.9, 2.1 Hz, 1H), 7.70–7.64
(m, 2H), 7.56–7.52 (m, 2H), 7.42 (d, J=8.2 Hz, 2H), 7.40–7.35 (m,
2H), 5.59 (s, 2H), 3.45 (s, 2H), 2.22 ppm (s, 6H); 13C NMR (150 MHz,
[D6]acetone): d=160.08, 145.14, 140.53, 138.16, 137.29, 135.50,
133.83, 133.32, 130.63, 130.55, 130.11, 129.61, 129.48, 129.25,
128.19, 128.03, 117.97, 67.83, 64.43, 45.63 ppm; HRMS (ESI-TOF, m/
z): calcd for C25H23
81BrClN2O [M+H]
+ 483.0656, found 483.0639.
2-([1,1’-Biphenyl]-4-ylmethoxy)-6-bromo-3-(4-((dimethylamino)-
methyl)phenyl)quinoline (34k): The procedure used to synthesize
34a was repeated using 33a and [1,1’-biphenyl]-4-ylmethanol to
afford compound 34k as a yellow solid in 89.8% yield; mp: 96–
97 8C. 1H NMR (600 MHz, [D6]acetone): d=8.22 (s, 1H), 8.13 (d, J=
2.2 Hz, 1H), 7.82 (d, J=8.9 Hz, 1H), 7.77 (dd, J=8.9, 2.2 Hz, 1H),
7.70 (d, J=8.2 Hz, 2H), 7.68–7.63 (m, 4H), 7.61 (d, J=8.3 Hz, 2H),
7.48–7.43 (t, J=7.8 Hz, 2H), 7.42 (d, J=8.2 Hz, 2H), 7.35 (t, J=
7.4 Hz, 1H), 5.66 (s, 2H), 3.45 (s, 2H), 2.21 ppm (s, 6H); 13C NMR
(150 MHz, [D6]acetone): d=160.27, 145.22, 141.46, 141.26, 140.48,
138.11, 137.44, 135.59, 133.28, 130.62, 130.14, 129.70, 129.63,
129.47, 129.38, 128.25, 128.21, 128.02, 127.71, 127.69, 117.89, 68.36,
64.44, 45.62 ppm; HRMS (ESI-TOF, m/z): calcd for C31H28ON2Br [M+
H]+ 523.1380, found 523.1389.
2-(4-(Benzyloxy)phenoxy)-6-bromo-3-(4-((dimethylamino)me-
thyl)phenyl)quinoline (34 l): The procedure used to synthesize
34a was repeated using 33a and 4-(benzyloxy)phenol to afford
compound 34 l as a yellow solid in 79.9% yield; mp: 103–104 8C.
1H NMR (600 MHz, [D6]acetone): d=8.31 (s, 1H), 8.15 (s, 1H), 7.77
(d, J=7.8 Hz, 2H), 7.71 (dd, J=8.9, 1.3 Hz, 1H), 7.55 (d, J=8.9 Hz,
1H), 7.51 (d, J=7.6 Hz, 2H), 7.46 (d, J=7.9 Hz, 2H), 7.41 (t, J=
7.5 Hz, 2H), 7.34 (t, J=7.3 Hz, 1H), 7.20 (d, J=8.8 Hz, 2H), 7.08 (d,
J=8.8 Hz, 2H), 5.14 (s, 2H), 3.47 (s, 2H), 2.22 ppm (s, 6H); 13C NMR
(150 MHz, [D6]acetone): d=160.75, 156.90, 148.20, 144.98, 140.61,
138.87, 138.41, 135.53, 133.41, 130.58, 130.17, 129.79, 129.61,
129.29, 128.65, 128.49, 128.36, 123.79, 118.44, 116.20, 70.85, 64.43,
45.64 ppm; HRMS (ESI-TOF, m/z): calcd for C31H28BrN2O2 [M+H]
+
539.1329, found 539.1334.
6-Bromo-3-(4-((dimethylamino)methyl)phenyl)-2-(pyridin-4-ylme-
thoxy)quinoline (34m): The procedure used to synthesize 34a
Table 7. In vitro antitubercular activities (MIC values) against drug-resistant clinical isolates of M. tuberculosis.
Compd: 34m 32e 34 i 32d INH RFP
mgmL@1 mm mgmL@1 mm mgmL@1 mm mgmL@1 mm mgmL@1 mm mgmL@1 mm
12153[a] 0.48 1.07 0.94 1.57 2.62 5.45 0.51 0.94 >40 >291 2.11 2.56
6133[a] 0.55 1.22 0.69 1.15 1.83 3.81 3.42 6.35 >40 >291 >40 >48
H37RV 0.43 0.95 0.44 0.73 0.33 0.68 0.46 0.85 0.05 0.36 0.05 0.06
[a] Strain number of in vitro cultured clinical isolate of MDR M. tuberculosis.
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was repeated using 33a and 4-pyridylcarbinol to afford compound
34m as a white solid in 84.7% yield; mp: 86–87 8C. 1H NMR
(600 MHz, [D6]acetone): d=8.54 (dd, J=4.4, 1.5 Hz, 2H), 8.24 (s,
1H), 8.13 (s, 1H), 7.76 (d, J=1.3 Hz, 2H), 7.71 (d, J=8.2 Hz, 2H),
7.47 (d, J=8.0 Hz, 2H), 7.44 (d, J=5.9 Hz, 2H), 5.65 (s, 2H), 3.49 (s,
2H), 2.24 ppm (s, 6H); 13C NMR (150 MHz, [D6]acetone): d=159.83,
150.65, 147.16, 145.07, 140.45, 138.30, 135.47, 133.38, 130.65,
130.16, 129.62, 129.58, 128.17, 128.09, 122.65, 118.11, 66.97, 64.37,
45.55 ppm; HRMS (ESI-TOF, m/z): calcd for C24H23BrN3O [M+H]
+
448.1019, found 448.1016.
2-(Benzylthio)-6-bromo-3-(4-((dimethylamino)methyl)phenyl)qui-
noline (34n): The procedure used to synthesize 34a was repeated
using 33a and benzyl mercaptan to afford compound 34n as
a yellow solid in 71.4% yield; mp: 67–68 8C. 1H NMR (600 MHz,
[D6]acetone): d=8.13 (s, 1H), 7.98 (d, J=8.9 Hz, 1H), 7.96 (s, 1H),
7.83 (d, J=8.9 Hz, 1H), 7.49 (d, J=7.8 Hz, 2H), 7.47 (d, J=8.0 Hz,
2H), 7.43 (d, J=7.9 Hz, 2H), 7.28 (t, J=7.5 Hz, 2H), 7.20 (t, J=
7.3 Hz, 1H), 4.56 (s, 2H), 3.46 (s, 2H), 2.21 ppm (s, 6H); 13C NMR
(150 MHz, [D6]acetone): d=160.10, 146.51, 141.09, 139.18, 136.75,
136.21, 135.16, 133.62, 130.81, 130.39, 130.21, 130.04, 129.67,
129.19, 128.33, 127.81, 119.27, 64.41, 45.64, 35.22 ppm; HRMS (ESI-
TOF, m/z): calcd for C25H24BrN2S [M+H]
+ 463.0844, found 463.0844.
Minimum inhibitory concentration and cytotoxicity assays : The
assays were performed following our previously published proto-
cols.[28–30]
Luminescence-based ATP synthesis inhibition assays and calcu-
lation of IC50 values : Mycobacterium phlei cells were grown and in-
verted membrane vesicles (IMVs) were prepared as described.[14]
IMVs were frozen and stored in liquid nitrogen until further use. To
assay ATP synthesis activity, an aliquot of IMVs were thawed on ice,
and 4 mm malonate was added. After 1 h of incubation, 25 mg
total protein in the IMVs were mixed with 270 mL reaction buffer
(20 mm Tricine/KOH pH 7.5, 0.1m NaCl, 5 mm KPi, 5 mm MgCl2),
50 mm ADP, 50 ng luciferase (Roche), 166 mm luciferin, and 2 mL
DMSO to a total volume of 300 mL. The addition of inhibitors was
varied in the concentration range of 0.5–100 mm. After incubation
for 10 min at room temperature the ATP synthesis reaction was
started by the addition of 10 mm succinate (pH 7.8). The synthesis
of ATP was monitored by an increasing luminescence signal using
a Sirius L single-tube Luminometer (Berthold). As an internal stan-
dard, 8 nm ATP was added after each reaction. The data were eval-
uated and the inhibitory concentrations of 50% (IC50) were calcu-
lated using Microsoft Excel and GraphPad Prism (version 7.0a).
Notes : The authors declare no competing financial interest.
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